Home World News Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic... World News Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic Hodgkin’s Lymphoma By Ogkologos - October 30, 2024 3462 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the S1826 study Source RELATED ARTICLESMORE FROM AUTHOR New on NCI’s Websites for November 2024 A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival in Patients with Locally Advanced Cervical Cancer Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board, Improves Outcomes In Pretreated Patients with Metastatic Cancer MOST POPULAR Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin June 19, 2026 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout July 29, 2021 FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma... April 11, 2025 Load more HOT NEWS COVID-19: “We’re having to rebuild and adapt because of coronavirus” FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... A Novel Model Helps Better Predict Risk of Cancer Development in...
